Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy
- 31 July 2008
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 22 (12) , 1417-1423
- https://doi.org/10.1097/qad.0b013e3283034953
Abstract
Background: The transmission of drug-resistant HIV-1 can impair the virological response to antiretroviral therapy. Minority-resistant variants have been detected in acute seroconverters. We investigated the clinical relevance of the detection of majority and minority-resistant variants in an observational study in antiretroviral therapy naive, recently infected patients. Methods: We included patients infected between 1996 and 2005, with a plasma sample obtained less than 18 months after seroconversion and prior to antiretroviral therapy initiation. Majority-resistant variants were determined by direct population sequencing. Minority-resistant variants were searched by allele-specific PCR for the mutations K103N and M184V in reverse transcriptase and L90M in protease. The association between resistance and viroimmunological response to antiretroviral therapy was estimated by using a piecewise linear mixed model. Results: Majority-resistant variants were detected in 23/172 (13.4%) patients. Patients with majority-resistant variants had a lower mean plasma viral load and higher mean CD4 cell count at baseline compared with those without resistance. The decrease in viral load between 1 and 6 months on antiretroviral therapy was significantly steeper in patients with sensitive viruses compared with those with majority-resistant variants (P = 0.029). Minority-resistant variants were detected in 21/73 (29%) patients with wild-type viruses at sequencing analysis. The presence of minority-resistant variants did not modify baseline viral load and CD4 cell count and did not affect the changes in viral load and CD4 cell count. Conclusion: The transmission of majority-resistant variants, but not minority-resistant variants, influenced the response to antiretroviral therapy in this prospective study. The detection of the transmission of minority-resistant variants warrants further clinical validation.Keywords
This publication has 16 references indexed in Scilit:
- High Rates of Forward Transmission Events after Acute/Early HIV‐1 InfectionThe Journal of Infectious Diseases, 2007
- Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)AIDS, 2006
- The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapyAIDS, 2006
- Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance AlgorithmsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Prevalence of Drug‐Resistant HIV‐1 Variants in Untreated Individuals in Europe: Implications for Clinical ManagementThe Journal of Infectious Diseases, 2005
- The Epidemiology of Antiretroviral Drug Resistance among Drug‐Naive HIV‐1–Infected Persons in 10 US CitiesThe Journal of Infectious Diseases, 2004
- Mixed models for longitudinal left-censored repeated measuresComputer Methods and Programs in Biomedicine, 2004
- Emergence of Minor Populations of Human Immunodeficiency Virus Type 1 Carrying the M184V and L90M Mutations in Subjects Undergoing Structured Treatment InterruptionsThe Journal of Infectious Diseases, 2003
- Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2003
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIVNew England Journal of Medicine, 2002